Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region

Cover Page


Sulfonylureas (SU) are widely used in everyday clinical practice in treatment of patients with type 2 diabetes mellitus (T2DM). There is a considerable variability in SU effects, which may be caused by psychological, social, biological and genetic factors. The aim of the study was to investigate the association between rs5219 KCNJ11 gene and rs757110 ABCC8 gene polymorphism and long-term response to SU-drugs of second and third generation in the Novosibirsk region.
Materials and Methods.
326 patients with type 2 diabetes in the Novosibirsk region were examined. Patients were divided into 2 groups, depending on HbA1c level. The first group included patients with target HbA1c levels on SU monotherapy. The second group included patients who did not reach target HbA1c levels on the highest dose of SU. Genotyping of KCNJ11 (rs5219) and ABCC8 (rs757110) was performed by TaqMan real-time PCR (ICBFM SB RAS, Novosibirsk, Russia).
Patients with type 2 diabetes with a good response to SU-therapy compared to the group of patients with a poor response to SU-therapy were older (65.8?9.1 years vs. 61.6?7.9 years, p<0.01), had later onset of type 2 diabetes (59.7?9.2 years vs. 48.3?9.3 years, p <0.01), shorter duration of type 2 diabetes (6.1?4.8 years vs. 13.2?7.3 years, p<0.01) and weak insulin resistance: fasting insulin 9.7?6.9 mU/ml vs. 13.6?12.7 mU/ml (p<0.05), HOMA-IR 3.1?2.2 vs. 6.2?6.0 (p<0.01), triglycerides 1.76?0.83 mmol/l vs. 2.42?1.97 mmol/l (p <0.01). Statistically significant differences between KCNJ11 (rs5219) and ABCC8 (rs757110) genotypes and response to SU-therapy was not found. The frequency of risk allele T polymorphism rs5219 KCNG11 gene in patients with a good response to SU was 0.38 and in the patients with a poor response to SU -0.38 (?2=0.02, р=0.89). The frequency of the risk allele G polymorphism rs757110 ABCC8 gene in patients with a good response to SU was 0.40 and in the patients with poor response to SU -0.37 (?2=0.34, р=0.56).
Patients with type 2 diabetes, who showed poor response to SU-therapy had a longer duration of diabetes, earlier diabetes onset, stronger insulin resistance compared to patients with a good response to SU-therapy. No correlation between rs5219 KCNJ11 gene and rs757110 ABCC8 gene polymorphism and long-term response to SU-therapy in T2DM patients in the Novosibirsk region was found.

About the authors

Irina Arkad'evna Bondar

Novosibirsk State Medical University, Novosibirsk


Russian Federation MD, PhD, Professor, Cheif of the Endocrinology Chair

Maksim Leonidovich Filipenko

Institute of Chemical Biology and Fundamental Medicine, Novosibirsk; Novosibirsk State University, Novosibirsk


Russian Federation PhD, Head of the pharmacogenomic laboratory

Olesya Yur'evna Shabel'nikova

Institute of Chemical Biology and Fundamental Medicine, Novosibirsk; Novosibirsk State University, Novosibirsk

Author for correspondence.

Russian Federation MD, PhD, Head of the Regional diabetes centre

Ekaterina Alexeevna Sokolova

Novosibirsk State Medical University, Novosibirsk; Novosibirsk State Regional Hospital, Novosibirsk


Russian Federation engineer of the pharmacogenomic laboratory


  1. OECD. Health at a Glance: Europe 2012. OECD Publishing; 2012.
  2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0
  3. International Diabetes Federation treatment algorithm for people with type 2 diabetes. 2012. Available from: http://www.idf.otg/Global_guideline/
  4. Belsey J, Krishnarajah G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. Diabetes, obesity & metabolism. 2008;10 Suppl 1:1–7. doi: 10.1111/j.1463-1326.2008.00884.x.
  5. Best JD, Drury PL, Davis TM, et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes care. 2012;35(5):1165–1170. doi: 10.2337/dc11-1307
  6. Drury PL, Cundy T. Glycemic management of type 2 diabetes mellitus. The New England journal of medicine. 2012;367(2):182. doi: 10.1056/NEJMc1205238#SA2
  7. Shyng S-L, Nichols C. Octameric stoichiometry of the KATP channel complex. The Journal of general physiology. 1997;110(6):655–664.
  8. Ashcroft F, Gribble F. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42(8):903–919.
  9. Hattersley A, Bruining J, Shield J, et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric diabetes. 2009;10 Suppl 12:33–42. doi: 10.1111/j.1399-5448.2009.00571.x
  10. Pearson ER, Flechtner I, Njølstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. New England Journal of Medicine. 2006;355(5):467–477.
  11. Lang VY, Fatehi M, Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenetics and genomics. 2012;22(3):206–214. doi: 10.1097/FPC.0b013e32835001e7
  12. Qiu L, Na R, Xu R, et al. Quantitative assessment of the effect of KCNJ11 gene polymorphism on the risk of type 2 diabetes. PloS one. 2014;9(4):e93961. doi: 10.1371/journal.pone.0093961
  13. Gong B, Yu J, Li H, et al. The effect of KCNJ11 polymorphism on the risk of type 2 diabetes: a global meta-analysis based on 49 case-control studies. DNA and cell biology. 2012;31(5):801–810. doi: 10.1089/dna.2011.1445
  14. Qin LJ, Lv Y, Huang QY. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes. Genetics and molecular research: GMR. 2013;12(3):2990–3002. doi: 10.4238/2013.August.20.1
  15. Florez JC, Burtt N, de Bakker PI, et al. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes. 2004;53(5):1360–1368
  16. Gloyn AL, Hashim Y, Ashcroft SJ, et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabetic medicine: a journal of the British Diabetic Association. 2001;18(3):206–212.
  17. Klen J, Dolzan V, Janez A. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European journal of clinical pharmacology. 2014;70(4):421–428. doi: 10.1007/s00228-014-1641-x
  18. Feng Y, Mao G, Ren X, et al. Ser1369Ala Variant in Sulfonylurea Receptor Gene ABCC8 Is Associated With Antidiabetic Efficacy of Gliclazide in Chinese Type 2 Diabetic Patients. Diabetes care. 2008;31(10):1939–1944. doi: 10.2337/dc07-2248
  19. Zhang H, Liu X, Kuang H, et al. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes research and clinical practice. 2007;77(1):58–61. doi: 10.1016/j.diabres.2006.10.021
  20. Javorsky M, Klimcakova L, Schroner Z, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European journal of internal medicine. 2012;23(3):245–249. doi: 10.1016/j.ejim.2011.10.018
  21. Sesti G, Laratta E, Cardellini M, et al. The E23K Variant of KCNJ11 Encoding the Pancreatic β-Cell Adenosine 5′-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2006;91(6):2334–2339. doi: 10.1210/jc.2005-2323

Supplementary files

There are no supplementary files to display.



Abstract - 2579

PDF (Russian) - 856




Copyright (c) 2015 Bondar I.A., Filipenko M.L., Shabel'nikova O.Y., Sokolova E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies